July 1, 2026
Retatrutide vs Tirzepatide vs Semaglutide: Mechanism, Half-Life, and What It Means for Tracking
A plain-language comparison of the three most-discussed GLP-1 compounds — how their receptor targets, half-lives, and titration timelines differ, and what to log for each.
"Which one is actually better?" is the most common question in every GLP-1 community — usually about semaglutide, tirzepatide, and the newer retatrutide. They are related, but they are not the same drug, and the differences change how you titrate, what side effects to expect, and what a tracking log should capture. Here is the plain-language version.
The one-line difference: how many receptors
The simplest way to hold these three apart is by the number of gut-hormone receptors each one activates.
| Compound | Receptor targets | Dosing | Approval status |
|---|---|---|---|
| Semaglutide | GLP-1 only | Once weekly | Approved (Ozempic, Wegovy) |
| Tirzepatide | GLP-1 + GIP (dual) | Once weekly | Approved (Mounjaro, Zepbound) |
| Retatrutide | GLP-1 + GIP + glucagon (triple) | Once weekly | Investigational (Phase 3) |
Semaglutide is a single-receptor GLP-1 agonist. Tirzepatide adds GIP, a second incretin hormone. Retatrutide adds a third target, the glucagon receptor, which is why it is sometimes called a "triple agonist." More targets is not automatically "better" for everyone — it changes the side-effect and response profile.
Important: retatrutide is still investigational. As of writing it is in late-stage trials and is not an approved medicine. Treat community reports about it with extra caution.
Half-life and why it drives your schedule
All three are long-acting, once-weekly compounds, but the exact half-life shapes how long dose changes take to fully show up.
| Compound | Approximate half-life | Time to steady state |
|---|---|---|
| Semaglutide | About 7 days | 4 to 5 weeks |
| Tirzepatide | About 5 days | 4 weeks |
| Retatrutide | About 6 days (reported in trials) | 4 to 5 weeks |
Because steady state takes roughly a month, the full effect of any dose — good or bad — is not visible in the first week or two. This is the single most common tracking mistake: judging a dose after 7 days. Give a new dose 4 to 6 weeks of logged data before deciding it "is not working."
Side-effect profiles differ
GI side effects (nausea, constipation, diarrhoea) are common across all three, especially during titration. Reports from trials suggest the added glucagon activity of retatrutide can shift the profile — for example more attention to heart rate and energy — but the trial data is what matters here, not anecdotes. Whatever you run, a structured side-effect log tied to each dose is how you separate a titration bump from a real problem worth raising with a clinician.
What to log for each
The metrics that matter are similar, but the cadence differs slightly:
- Dose and date — every weekly injection, with the exact amount.
- Injection site — rotate and record; absorption varies by site.
- Weight trend — daily readings, but judge the weekly median, not any single morning.
- Side effects — severity and timing relative to the dose (same day, day 2, day 3).
- Titration step — note the week you moved up, so you can line up a 4-week window afterward.
The honest takeaway
There is no universal winner. Semaglutide has the longest safety record; tirzepatide adds a second mechanism many people respond well to; retatrutide is promising but still investigational. The compound matters less than running it consistently and reading your own logged data over a full steady-state window.
TrackPep lets you log all three as separate compounds with per-dose side-effect tracking and a trend-smoothed weight chart, so a switch or a titration step is always visible in the data — not a guess.
Educational only — not medical advice. Retatrutide is investigational. Always work with a licensed healthcare provider before starting, switching, or adjusting any GLP-1 therapy.